DIVALPROEX Drug Patent Profile
✉ Email this page to a colleague
When do Divalproex patents expire, and what generic alternatives are available?
Divalproex is a drug marketed by Ajanta Pharma Ltd, Alembic, Dr Reddys Labs Ltd, Mankind Pharma, Rising, Teva Pharms Usa, Zydus Pharms Usa Inc, Actavis Labs Fl Inc, Apotex, Aurobindo Pharma Ltd, Chartwell Rx, Invatech, Lupin, Mylan, Orbion Pharms, Ph Health, Pharmobedient, Prinston Inc, Sun Pharm Inds, Teva, Unichem Labs Ltd, Upsher Smith Labs, Amneal Pharms, Annora Pharma, Cosette, Impax Labs, Reddys, Sciegen Pharms, Unichem, and Yichang Humanwell. and is included in thirty-eight NDAs.
The generic ingredient in DIVALPROEX is divalproex sodium. There are eighteen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Divalproex
A generic version of DIVALPROEX was approved as divalproex sodium by DR REDDYS LABS LTD on July 29th, 2008.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DIVALPROEX?
- What are the global sales for DIVALPROEX?
- What is Average Wholesale Price for DIVALPROEX?
Summary for DIVALPROEX
| US Patents: | 0 |
| Applicants: | 30 |
| NDAs: | 38 |
| Drug Prices: | Drug price information for DIVALPROEX |
| Drug Sales Revenues: | Drug sales revenues for DIVALPROEX |
| DailyMed Link: | DIVALPROEX at DailyMed |
US Patents and Regulatory Information for DIVALPROEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sciegen Pharms | DIVALPROEX SODIUM | divalproex sodium | TABLET, EXTENDED RELEASE;ORAL | 078705-002 | Feb 10, 2009 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sun Pharm Inds | DIVALPROEX SODIUM | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 078597-002 | Jul 29, 2008 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Orbion Pharms | DIVALPROEX SODIUM | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 078853-003 | Nov 25, 2008 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Upsher Smith Labs | DIVALPROEX SODIUM | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 078182-001 | Jul 29, 2008 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Aurobindo Pharma Ltd | DIVALPROEX SODIUM | divalproex sodium | TABLET, EXTENDED RELEASE;ORAL | 202419-002 | Jun 2, 2014 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Teva | DIVALPROEX SODIUM | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 076941-003 | Jul 29, 2008 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Upsher Smith Labs | DIVALPROEX SODIUM | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 078182-002 | Jul 29, 2008 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
